Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Price Up 2% – Should You Buy?

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS)’s stock price rose 2% during mid-day trading on Thursday . The stock traded as high as $0.7132 and last traded at $0.7009. Approximately 11,888 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 23,245 shares. The stock had previously closed at $0.6870.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.00.

Barinthus Biotherapeutics Price Performance

The stock has a market capitalization of $28.31 million, a price-to-earnings ratio of -0.54 and a beta of -0.43. The business has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.69.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baird Financial Group Inc. grew its stake in Barinthus Biotherapeutics by 108.2% in the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after acquiring an additional 100,000 shares during the period. Renaissance Technologies LLC grew its stake in Barinthus Biotherapeutics by 115.8% in the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after acquiring an additional 76,800 shares during the period. Finally, Rangeley Capital LLC grew its stake in Barinthus Biotherapeutics by 88.8% in the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after acquiring an additional 75,024 shares during the period. 25.20% of the stock is owned by institutional investors and hedge funds.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.